Does the media refer more to TSHA or HHH?

In the previous week, Howard Hughes had 4 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 6 mentions for Howard Hughes and 2 mentions for Taysha Gene Therapies. Howard Hughes' average media sentiment score of 0.93 beat Taysha Gene Therapies' score of 0.34 indicating that Howard Hughes is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Taysha Gene Therapies 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Howard Hughes 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TSHA or PTCT?

In the previous week, PTC Therapeutics had 12 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 14 mentions for PTC Therapeutics and 2 mentions for Taysha Gene Therapies. PTC Therapeutics' average media sentiment score of 0.46 beat Taysha Gene Therapies' score of 0.34 indicating that PTC Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Taysha Gene Therapies 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PTC Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to LNTH or TSHA?

In the previous week, Lantheus had 5 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 7 mentions for Lantheus and 2 mentions for Taysha Gene Therapies. Lantheus' average media sentiment score of 0.71 beat Taysha Gene Therapies' score of 0.34 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Taysha Gene Therapies 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is SRRK or TSHA more profitable?

Taysha Gene Therapies' return on equity of -56.07% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Scholar Rock N/A -163.52% -96.67% Taysha Gene Therapies N/A -56.07% -40.16%

Does the media favor SRRK or TSHA?

In the previous week, Scholar Rock had 1 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 3 mentions for Scholar Rock and 2 mentions for Taysha Gene Therapies. Scholar Rock's average media sentiment score of 1.10 beat Taysha Gene Therapies' score of 0.34 indicating that Scholar Rock is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Taysha Gene Therapies 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is TSHA or XENE more profitable?

Xenon Pharmaceuticals' return on equity of -49.23% beat Taysha Gene Therapies' return on equity. Company Net Margins Return on Equity Return on Assets Taysha Gene Therapies N/A -56.07% -40.16% Xenon Pharmaceuticals N/A -49.23% -46.42%

Does the media refer more to TSHA or XENE?

In the previous week, Xenon Pharmaceuticals had 4 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 6 mentions for Xenon Pharmaceuticals and 2 mentions for Taysha Gene Therapies. Xenon Pharmaceuticals' average media sentiment score of 1.49 beat Taysha Gene Therapies' score of 0.34 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Taysha Gene Therapies 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Xenon Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Taysha Gene Therapies (TSHA) Competitors

$5.60 -0.36 (-5.96%)

Closing price 03:59 PM Eastern

Extended Trading

$5.58 -0.02 (-0.43%)

As of 04:07 PM Eastern

Compare

TSHA vs. HHH, PTCT, LNTH, SRRK, and XENE

Should you buy Taysha Gene Therapies stock or one of its competitors? MarketBeat compares Taysha Gene Therapies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Taysha Gene Therapies include Howard Hughes (HHH), PTC Therapeutics (PTCT), Lantheus (LNTH), Scholar Rock (SRRK), and Xenon Pharmaceuticals (XENE).

How does Taysha Gene Therapies compare to Howard Hughes?

Taysha Gene Therapies (NASDAQ:TSHA) and Howard Hughes (NYSE:HHH) are related companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, dividends, valuation and earnings.

Howard Hughes has a net margin of 8.04% compared to Taysha Gene Therapies' net margin of 0.00%. Howard Hughes' return on equity of 5.41% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Taysha Gene Therapies	N/A	-56.07%	-40.16%
Howard Hughes	8.04%	5.41%	1.61%

Taysha Gene Therapies has a beta of 1.17, meaning that its share price is 17% more volatile than the broader market. Comparatively, Howard Hughes has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market.

Taysha Gene Therapies currently has a consensus target price of $12.62, suggesting a potential upside of 122.30%. Howard Hughes has a consensus target price of $79.00, suggesting a potential upside of 15.19%. Given Taysha Gene Therapies' stronger consensus rating and higher probable upside, equities research analysts plainly believe Taysha Gene Therapies is more favorable than Howard Hughes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00
Howard Hughes	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Howard Hughes has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Howard Hughes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Taysha Gene Therapies	$9.77M	166.92	-$109M	-$0.38	N/A
Howard Hughes	$1.47B	2.77	$131.88M	$2.04	33.62

In the previous week, Howard Hughes had 4 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 6 mentions for Howard Hughes and 2 mentions for Taysha Gene Therapies. Howard Hughes' average media sentiment score of 0.93 beat Taysha Gene Therapies' score of 0.34 indicating that Howard Hughes is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Taysha Gene Therapies	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Howard Hughes	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

77.7% of Taysha Gene Therapies shares are held by institutional investors. Comparatively, 93.8% of Howard Hughes shares are held by institutional investors. 3.5% of Taysha Gene Therapies shares are held by insiders. Comparatively, 48.0% of Howard Hughes shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Howard Hughes beats Taysha Gene Therapies on 11 of the 17 factors compared between the two stocks.

How does Taysha Gene Therapies compare to PTC Therapeutics?

Taysha Gene Therapies (NASDAQ:TSHA) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.

In the previous week, PTC Therapeutics had 12 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 14 mentions for PTC Therapeutics and 2 mentions for Taysha Gene Therapies. PTC Therapeutics' average media sentiment score of 0.46 beat Taysha Gene Therapies' score of 0.34 indicating that PTC Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Taysha Gene Therapies	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PTC Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

77.7% of Taysha Gene Therapies shares are held by institutional investors. 3.5% of Taysha Gene Therapies shares are held by company insiders. Comparatively, 5.5% of PTC Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Taysha Gene Therapies currently has a consensus price target of $12.62, indicating a potential upside of 122.30%. PTC Therapeutics has a consensus price target of $92.29, indicating a potential upside of 18.17%. Given Taysha Gene Therapies' stronger consensus rating and higher probable upside, equities analysts plainly believe Taysha Gene Therapies is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00
PTC Therapeutics	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.80

Taysha Gene Therapies has a net margin of 0.00% compared to PTC Therapeutics' net margin of -22.58%. Taysha Gene Therapies' return on equity of -56.07% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Taysha Gene Therapies	N/A	-56.07%	-40.16%
PTC Therapeutics	-22.58%	-362.45%	-6.76%

Taysha Gene Therapies has a beta of 1.17, meaning that its share price is 17% more volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market.

PTC Therapeutics has higher revenue and earnings than Taysha Gene Therapies. PTC Therapeutics is trading at a lower price-to-earnings ratio than Taysha Gene Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Taysha Gene Therapies	$9.77M	166.92	-$109M	-$0.38	N/A
PTC Therapeutics	$1.73B	3.74	$682.64M	-$2.33	N/A

Summary

Taysha Gene Therapies beats PTC Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Taysha Gene Therapies compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Taysha Gene Therapies (NASDAQ:TSHA) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.

Lantheus has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.46	$233.56M	$4.15	25.42
Taysha Gene Therapies	$9.77M	166.92	-$109M	-$0.38	N/A

In the previous week, Lantheus had 5 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 7 mentions for Lantheus and 2 mentions for Taysha Gene Therapies. Lantheus' average media sentiment score of 0.71 beat Taysha Gene Therapies' score of 0.34 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Taysha Gene Therapies	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lantheus has a beta of -0.06, suggesting that its stock price is 106% less volatile than the broader market. Comparatively, Taysha Gene Therapies has a beta of 1.17, suggesting that its stock price is 17% more volatile than the broader market.

99.1% of Lantheus shares are owned by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are owned by institutional investors. 1.7% of Lantheus shares are owned by insiders. Comparatively, 3.5% of Taysha Gene Therapies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Lantheus has a net margin of 18.05% compared to Taysha Gene Therapies' net margin of 0.00%. Lantheus' return on equity of 29.32% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
Taysha Gene Therapies	N/A	-56.07%	-40.16%

Lantheus presently has a consensus price target of $110.43, indicating a potential upside of 4.68%. Taysha Gene Therapies has a consensus price target of $12.62, indicating a potential upside of 122.30%. Given Taysha Gene Therapies' stronger consensus rating and higher probable upside, analysts plainly believe Taysha Gene Therapies is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Lantheus beats Taysha Gene Therapies on 10 of the 17 factors compared between the two stocks.

How does Taysha Gene Therapies compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and Taysha Gene Therapies (NASDAQ:TSHA) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership.

91.1% of Scholar Rock shares are owned by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are owned by institutional investors. 10.3% of Scholar Rock shares are owned by insiders. Comparatively, 3.5% of Taysha Gene Therapies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Scholar Rock has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market. Comparatively, Taysha Gene Therapies has a beta of 1.17, meaning that its share price is 17% more volatile than the broader market.

In the previous week, Scholar Rock had 1 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 3 mentions for Scholar Rock and 2 mentions for Taysha Gene Therapies. Scholar Rock's average media sentiment score of 1.10 beat Taysha Gene Therapies' score of 0.34 indicating that Scholar Rock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Taysha Gene Therapies	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Scholar Rock presently has a consensus target price of $56.00, suggesting a potential upside of 9.42%. Taysha Gene Therapies has a consensus target price of $12.62, suggesting a potential upside of 122.30%. Given Taysha Gene Therapies' higher probable upside, analysts plainly believe Taysha Gene Therapies is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00

Taysha Gene Therapies' return on equity of -56.07% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-163.52%	-96.67%
Taysha Gene Therapies	N/A	-56.07%	-40.16%

Taysha Gene Therapies has higher revenue and earnings than Scholar Rock. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A
Taysha Gene Therapies	$9.77M	166.92	-$109M	-$0.38	N/A

Summary

Scholar Rock beats Taysha Gene Therapies on 8 of the 15 factors compared between the two stocks.

How does Taysha Gene Therapies compare to Xenon Pharmaceuticals?

Taysha Gene Therapies (NASDAQ:TSHA) and Xenon Pharmaceuticals (NASDAQ:XENE) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations and media sentiment.

77.7% of Taysha Gene Therapies shares are owned by institutional investors. Comparatively, 95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. 3.5% of Taysha Gene Therapies shares are owned by company insiders. Comparatively, 2.9% of Xenon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Xenon Pharmaceuticals' return on equity of -49.23% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Taysha Gene Therapies	N/A	-56.07%	-40.16%
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%

Taysha Gene Therapies currently has a consensus price target of $12.62, suggesting a potential upside of 122.30%. Xenon Pharmaceuticals has a consensus price target of $77.20, suggesting a potential upside of 15.42%. Given Taysha Gene Therapies' higher probable upside, research analysts clearly believe Taysha Gene Therapies is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Xenon Pharmaceuticals had 4 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 6 mentions for Xenon Pharmaceuticals and 2 mentions for Taysha Gene Therapies. Xenon Pharmaceuticals' average media sentiment score of 1.49 beat Taysha Gene Therapies' score of 0.34 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Taysha Gene Therapies	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xenon Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Taysha Gene Therapies has a beta of 1.17, meaning that its stock price is 17% more volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market.

Taysha Gene Therapies has higher revenue and earnings than Xenon Pharmaceuticals. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Taysha Gene Therapies	$9.77M	166.92	-$109M	-$0.38	N/A
Xenon Pharmaceuticals	$7.50M	862.14	-$345.91M	-$4.70	N/A

Summary

Taysha Gene Therapies and Xenon Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

Get Taysha Gene Therapies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TSHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TSHA vs. The Competition

Export

Metric	Taysha Gene Therapies	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.63B	$6.33B	$6.80B	$12.31B
Dividend Yield	N/A	0.69%	2.67%	9.36%
P/E Ratio	-14.93	9.54	27.16	24.03
Price / Sales	166.92	22.75	573.71	113.02
Price / Cash	N/A	8.30	29.05	48.09
Price / Book	6.31	4.24	10.67	6.16
Net Income	-$109M	$99.67M	$3.59B	$331.63M
7 Day Performance	5.48%	-0.31%	-1.46%	-1.53%
1 Month Performance	-11.60%	5.91%	1.20%	-1.24%
1 Year Performance	120.82%	125.27%	24.36%	17.49%

Taysha Gene Therapies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TSHA Taysha Gene Therapies	3.2377 of 5 stars	$5.61 -6.0%	$12.62 +125.1%	+131.9%	$1.61B	$9.77M	N/A	180
HHH Howard Hughes	3.5575 of 5 stars	$71.72 -0.5%	$85.00 +18.5%	+2.5%	$4.30B	$1.47B	35.16	608	Analyst Forecast
PTCT PTC Therapeutics	3.4125 of 5 stars	$81.33 -4.1%	$91.57 +12.6%	+65.0%	$7.04B	$1.73B	N/A	1,410	Analyst Forecast
LNTH Lantheus	2.7547 of 5 stars	$105.39 -0.2%	$108.29 +2.7%	+53.3%	$6.88B	$1.54B	25.40	1,193	Positive News
SRRK Scholar Rock	1.9946 of 5 stars	$54.70 -3.5%	$56.00 +2.4%	+29.8%	$6.80B	N/A	N/A	140	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TSHA) was last updated on 7/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Taysha Gene Therapies (TSHA) Competitors

TSHA vs. HHH, PTCT, LNTH, SRRK, and XENE

How does Taysha Gene Therapies compare to Howard Hughes?

Summary

How does Taysha Gene Therapies compare to PTC Therapeutics?

Summary

How does Taysha Gene Therapies compare to Lantheus?

Summary

How does Taysha Gene Therapies compare to Scholar Rock?

Summary

How does Taysha Gene Therapies compare to Xenon Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TSHA vs. The Competition

Taysha Gene Therapies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Taysha Gene Therapies (TSHA) Competitors

TSHA vs. HHH, PTCT, LNTH, SRRK, and XENE

How does Taysha Gene Therapies compare to Howard Hughes?

Is TSHA or HHH more profitable?

Which has more volatility & risk, TSHA or HHH?

Do analysts prefer TSHA or HHH?

Which has better valuation and earnings, TSHA or HHH?

Does the media refer more to TSHA or HHH?

Do institutionals & insiders have more ownership in TSHA or HHH?

Summary

How does Taysha Gene Therapies compare to PTC Therapeutics?

Does the media prefer TSHA or PTCT?

Do institutionals & insiders believe in TSHA or PTCT?

Do analysts recommend TSHA or PTCT?

Is TSHA or PTCT more profitable?

Which has more risk and volatility, TSHA or PTCT?

Which has stronger earnings and valuation, TSHA or PTCT?

Summary

How does Taysha Gene Therapies compare to Lantheus?

Which has stronger earnings and valuation, LNTH or TSHA?

Does the media refer more to LNTH or TSHA?

Which has more volatility and risk, LNTH or TSHA?

Do insiders and institutionals have more ownership in LNTH or TSHA?

Is LNTH or TSHA more profitable?

Do analysts rate LNTH or TSHA?

Summary

How does Taysha Gene Therapies compare to Scholar Rock?

Do insiders & institutionals hold more shares of SRRK or TSHA?

Which has more volatility and risk, SRRK or TSHA?

Does the media favor SRRK or TSHA?

Do analysts recommend SRRK or TSHA?

Is SRRK or TSHA more profitable?

Which has stronger earnings & valuation, SRRK or TSHA?

Summary

How does Taysha Gene Therapies compare to Xenon Pharmaceuticals?

Do insiders & institutionals have more ownership in TSHA or XENE?

Is TSHA or XENE more profitable?

Do analysts rate TSHA or XENE?

Does the media refer more to TSHA or XENE?

Which has more risk & volatility, TSHA or XENE?

Which has stronger valuation and earnings, TSHA or XENE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TSHA vs. The Competition

Taysha Gene Therapies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools